Not admitted · Not a forecast

“It isn't MDMA itself that was rejected per se, but the specific, poor data set provided by Lykos; the committee particularly cited discrepancies in clinical trial design + conduct, inadequate collection of safety + other relevant data, bias in the evaluation of patients, and cases of patient abuse during the trials.”